Alzheimer’S Disease Dementia

LAS VEGAS — Lesser-known cannabinoids are showing potential for treating neurological disease, inflammation, pain, cancer and infection, according to dermatologist Jeanette Jacknin, MD.

In this edition, BMI is associated with dementia in women and linked with disease in men; Healthy diet, physical activity are linked to lower mortality in adults with PD; mild TBI and CT scans and more.

Alpha Cognition Inc. has announced positive results from a bioequivalence study with Alpha-1062, a proprietary, delayed release oral tablet formulation in development for the treatment of mild to moderate Alzheimer’s disease.

In this edition, leisure activities may lower risk for Alzheimer's disease and dementia; most common long COVID symptoms include fatigue and headache; ‘life-changing’ app-based digital therapeutic for tinnitus and more.

The FDA has declined to approve a supplemental new drug application for the expanded use of Nuplazid to treat psychosis related to Alzheimer's disease.

A thin optical fiber shows promise for use in minimally invasive deep tissue studies in brains affected by Alzheimer’s disease, researchers reported in APL Photonics.

Alzamend Neuro Inc. has announced the launch of a phase 2A trial for its AL001 treatment for mild to moderate Alzheimer’s dementia.

The FDA granted breakthrough device designation and permitted marketing for the first in vitro diagnostic test for early detection of amyloid plaques associated with Alzheimer’s disease.

The FDA has granted fast track designation for Vaxxinity Inc.’s UB-311, an anti-amyloid beta immunotherapeutic vaccine, for the treatment of Alzheimer’s disease.

Biopharmaceutical company Corium announced that the FDA has approved Adlarity to treat patients with mild, moderate or severe dementia associated with Alzheimer’s disease, according to a press release.